Tivozanib
Tivozanib, also known as KRN951, is an orally bioavailable vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3 inhibitor with potential anti-angiogenic and anti-tumor activity. Tivozanib binds and inhibits VEGFR 1, 2, and 3, potentially leading to inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis, and tumor cell death.
| Supplier | Alfa Cytology |
|---|---|
| Product # | BC0515 |
| Pricing | 5.0 mg, 10.0 mg, 25.0 mg, 50.0 mg, 100.0 mg, 200.0 mg, inquire |